Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes

Trial Profile

Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Semaglutide (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms SUSTAIN
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Feb 2017 According to a Novo Nordisk media release, based on the results from the SUSTAIN clinical trial programme, company has submitted NDA to the Japanese Ministry of Health, Labour and Welfare for semaglutide, administrated once-weekly, for the treatment of adults with type 2 diabetes. This filing follows the recent once-weekly semaglutide regulatory submissions to the US FDA, the European Medicines Agency (EMA).
    • 05 Dec 2016 According to a Novo Nordisk media release, company has submitted New Drug Application to the US Food and Drug Administration and a Marketing Authorisation Application to the European Medicines Agency for semaglutide administered once-weekly, for the treatment of adults with type 2 diabetes based on the results from the SUSTAIN clinical trial programme.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top